Liquidia Technologies, Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   Inhaled Treprostinil (LIQ861) · Pulmonary Arterial Hypertension…Inhaled Treprostinil (LIQ861) · Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

   Recruitment opened

   Liquidia Technologies, Inc.·Phase 4· NCT07759804· Registry history of NCT07759804 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.